

December 6, 2024

To whom it may concern:

Company Name Corporate Representative	TOHO HOLDINGS CO., LTD. Hiromi Edahiro, Representative Director, CEO and CFO (Prime Market of Tokyo Stock Exchange Securities Code: 8129)
Contact:	Makoto Kawamura, Corporate Officer and General Manager, Corporate Strategy Division (TEL: 81-3-6838-2803)

Notice Regarding Launch of KYOSOMIRAI PHARMA of
2 Ingredients / 3 Products of Generic Drugs

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Representative Director, CEO and CFO: Hiromi Edahiro) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Yasuyuki Kumada), the wholly-owned subsidiary involved in pharmaceuticals manufacturing and sales business, has launched 2 ingredients / 3 products of generic drugs today on December 6, 2024 as below.

New products list

Classes	Product Name	Original Brand Name
Nonsteroidal anti-Inflammatory drug (Selective COX-2 Inhibitors)	Celecoxib Tablets 100mg / 200mg “DAITO”	Celecox® Tablets 100mg / 200mg
Selective DPP-4 inhibitor (Type 2 diabetes mellitus)	Vildagliptin Tablets 50mg “TOWA”	Equa® Tablets 50mg